Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens

Vaccine

Volumn 31, Issue 42, 2013, Pages 4795-4801

  Iankov, Ianko D ^a   Federspiel, Mark J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chimeric antigens; Helicobacter pylori; Immunogenicity; Measles virus vaccine; Neutrophil activating protein

Indexed keywords

BACTERIAL PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN; NEUTROPHIL ACTIVATING PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELICOBACTER PYLORI; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; MEASLES VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS ATTENUATION; VIRUS NEUTRALIZATION;

CHIMERIC ANTIGENS; HELICOBACTER PYLORI; IMMUNOGENICITY; MEASLES VIRUS VACCINE; NEUTROPHIL-ACTIVATING PROTEIN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES; ANTIGENS; BACTERIAL PROTEINS; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; MEASLES VIRUS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTRALIZATION TESTS; RECOMBINANT PROTEINS;

EID: 84884203845     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.085     Document Type: Article

References (43)

1. Boudet F., Girard M., Theze J., Zouali M. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120. International Immunology 1992, 4:283-294.
2. Skinner M.A., Langlois A.J., McDanal C.B., McDougal J.S., Bolognesi D.P., Matthews T.J. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. Journal of Virology 1988, 62:4195-4200.
3. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. Journal of Virology 1993, 67:2552-2558.
4. Bui H.H., Peters B., Assarsson E., Mbawuike I., Sette A. Ab and T cell epitopes of influenza A virus, knowledge and opportunities. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:246-251.
5. Krause J.C., Tsibane T., Tumpey T.M., Huffman C.J., Basler C.F., Crowe J.E. A broadly neutralizing human monoclonal antibody that recognizes a conserved, novel epitope on the globular head of the influenza H1N1 virus hemagglutinin. Journal of Virology 2011, 85:10905-10908.
6. Barr T.A., Carlring J., Heath A.W. Co-stimulatory agonists as immunological adjuvants. Vaccine 2006, 24:3399-3407.
7. Soler E., Houdebine L.M. Preparation of recombinant vaccines. Biotechnology Annual Review 2007, 13:65-94.
8. Grange J.M., Bottasso O., Stanford C.A., Stanford J.L. The use of mycobacterial adjuvant-based agents for immunotherapy of cancer. Vaccine 2008, 26:4984-4990.
9. Shahabi V., Maciag P.C., Rivera S., Wallecha A. Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment. Bioengineered Bugs 2010, 1:235-243.
10. Singh M., Billeter M.A. A recombinant measles virus expressing biologically active human interleukin-12. Journal of General Virology 1999, 80:101-106.
11. Osada T., Berglund P., Morse M.A., Hubby B., Lewis W., Niedzwiecki D., et al. Kim Lyerly H. Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effects. Cancer Immunology, Immunotherapy 2012, 61:1941-1951.
12. Chengalvala M.V., Bhat R.A., Bhat B.M., Vernon S.K., Lubeck M.D. Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid. Vaccine 1999, 17:1035-1041.
13. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002, 99:1517-1526.
14. Satin B., Del Giudice G., Della Bianca V., Dusi S., Laudanna C., Tonello F., et al. The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. Journal of Experimental Medicine 2000, 191:1467-1476.
15. Tonello F., Dundon W.G., Satin B., Molinari M., Tognon G., Grandi G., et al. The Helicobacter pylori neutrophil-activating protein is an iron-binding protein with dodecameric structure. Molecular Microbiology 1999, 34:238-246.
16. Amedei A., Cappon A., Codolo G., Cabrelle A., Polenghi A., Benagiano M., et al. The neutrophil-activating protein of Helicobacter pylori promotes Th1 immune responses. Journal of Clinical Investigation 2006, 116:1092-1101.
17. Codolo G., Mazzi P., Amedei A., Del Prete G., Berton G., D'Elios M.M., et al. The neutrophil-activating protein of Helicobacter pylori down-modulates Th2 inflammation in ovalbumin-induced allergic asthma. Cellular Microbiology 2008, 10:2355-2363.
18. Del Prete G., Chiumiento L., Amedei A., Piazza M., D'Elios M.M., Codolo G., et al. Immunosuppression of TH2 responses in Trichinella spiralis infection by Helicobacter pylori neutrophil-activating protein. Journal of Allergy and Clinical Immunology 2008, 122:908-913.
19. Codolo G., Fassan M., Munari F., Volpe A., Bassi P., Rugge M., et al. HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response. Cancer Immunology, Immunotherapy 2012, 61:31-40.
20. Kottakis F., Papadopoulos G., Pappa E.V., Cordopatis P., Pentas S., Choli-Papadopoulou T. Helicobacter pylori neutrophil-activating protein activates neutrophils by its C-terminal region even without dodecamer formation, which is a prerequisite for DNA protection - novel approaches against Helicobacter pylori inflammation. FEBS Journal 2008, 275:302-317.
21. Iankov I.D., Haralambieva I.H., Galanis E. Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. Vaccine 2011, 29:1710-1720.
22. Iankov I.D., Penheiter A.R., Carlson S.K., Galanis E. Development of monoclonal antibody-based immunoassays for detection of Helicobacter pylori neutrophil-activating protein. Journal of Immunological Methods 2012, 384:1-9.
23. Iankov I.D., Allen C., Federspiel M.J., Myers R.M., Peng K.W., Ingle J.N., et al. Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus. Molecular Therapy 2012, 20:1139-1147.
24. Iankov I.D., Hillestad M.L., Dietz A.B., Russell S.J., Galanis E. Converting tumor-specific markers into reporters of oncolytic virus infection. Molecular Therapy 2009, 17:1395-1403.
25. Dingli D., Peng K.W., Harvey M.E., Greipp P.R., O'Connor M.K., Cattaneo R., et al. Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood 2004, 103(5):1641-1646.
26. Langfield K.K., Walker H.J., Gregory L.C., Federspiel M.J. Manufacture of measles viruses. Methods in Molecular Biology 2011, 737:345-366.
27. Mrkic B., Pavlovic J., Rülicke T., Volpe P., Buchholz C.J., Hourcade D., et al. Measles virus spread and pathogenesis in genetically modified mice. Journal of Virology 1998, 72:7420-7427.
28. Mrkic B., Odermatt B., Klein M.A., Billeter M.A., Pavlovic J., Cattaneo R. Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. Journal of Virology 2000, 74:1364-1372.
29. Roscic-Mrkic B., Schwendener R.A., Odermatt B., Zuniga A., Pavlovic J., Billeter M.A., et al. Roles of macrophages in measles virus infection of genetically modified mice. Journal of Virology 2001, 75:3343-3351.
30. Iankov I.D., Pandey M., Harvey M., Griesmann G.E., Federspiel M.J., Russell S.J. Immunoglobulin G antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. Journal of Virology 2006, 80:8530-8540.
31. Song M.K., Vindurampulle C.J., Capozzo A.V., Ulmer J., Polo J.M., Pasetti M.F., et al. Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins. Journal of Virology 2005, 79:9854-9861.
32. Iankov I.D., Penheiter A.R., Griesmann G.E., Carlson S.K., Federspiel M.J., Galanis E. Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells. Virus Research 2013, 172:15-23.
33. Haralambieva I.H., Ovsyannikova I.G., Vierkant R.A., Poland G.A. Development of a novel efficient fluorescence-based plaque reduction microneutralization assay for measles virus immunity. Clinical and Vaccine Immunology 2008, 15:1054-1059.
34. Chen R.T., Markowitz L.E., Albrecht P., Stewart J.A., Mofenson L.M., Preblud S.R., et al. Measles antibody: reevaluation of protective titers. Journal of Infectious Diseases 1990, 162(5):1036-1042.
35. Ward B.J., Aouchiche S., Martel N., Bertley F.M., Bautista-Lopez N., Serhir B., et al. Measurement of measles virus-specific neutralizing antibodies: evaluation of the syncytium inhibition assay in comparison with the plaque reduction neutralization test. Diagnostic Microbiology and Infectious Disease 1999, 33(3):147-152.
36. Warshakoon H.J., Hood J.D., Kimbrell M.R., Malladi S., Wu W.Y., Shukla N.M., et al. Potential adjuvantic properties of innate immune stimuli. Human Vaccines 2009, 5:381-394.
37. Zuniga A., Wang Z., Liniger M., Hangartner L., Caballero M., Pavlovic J., et al. Attenuated measles virus as a vaccine vector. Vaccine 2007, 25:2974-2983.
38. Brandler S., Marianneau P., Loth P., LacÔte S., Combredet C., Frenkiel M.P., et al. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection. Journal of Infectious Diseases 2012, 206:212-219.
39. Stebbings R., Février M., Li B., Lorin C., Koutsoukos M., Mee E., et al. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS ONE 2012, 7:e50397.
40. del Valle J.R., Devaux P., Hodge G., Wegner N.J., McChesney M.B., Cattaneo R. A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. Journal of Virology 2007, 81:10597-10605.
41. Centers for Disease Control and Prevention (CDC) Global control and regional elimination of measles, 2000-2011. MMWR. Morbidity and Mortality Weekly Report 2013, 62:27-31.
42. Duprex W.P., McQuaid S., Hangartner L., Billeter M.A., Rima B.K. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. Journal of Virology 1999, 73:9568-9575.
43. Bouche F.B., Ertl O.T., Muller C.P. Neutralizing B cell response in measles. Viral Immunology 2002, 15:451-471.